As controversy rises over equal access to Covid-19 medical products, a manufacturer of rapid, point-of care tests is being urged to lower the price of its diagnostic and also increase sales to a World Health Organization diagnostics consortium designed to serve low-income countries.

At issue is a test developed by Cepheid, which charges $19.80 for the test for 145 developing countries represented by the consortium. Doctors Without Borders argues the company could still make a profit if the price was lowered to $5. The relief organization extrapolated data from an analysis of a Cepheid test for tuberculosis, which found expenses amounted to $3 in production cost, at high sales volumes.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy